$UBX
Unity Biotechnology, Inc.

2018 Q4 Form 10-K Financial Statement

#000156459020010071 Filed on March 11, 2020

View on sec.gov

Income Statement

Concept 2018 Q4 2018 Q3 2018 Q2
Revenue $0.00 $0.00 $0.00
YoY Change -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.330M $4.390M $3.840M
YoY Change 67.83% 77.02% 54.22%
% of Gross Profit
Research & Development $16.33M $14.35M $15.20M
YoY Change 40.9% 49.53% 64.96%
% of Gross Profit
Depreciation & Amortization $600.0K $560.0K $520.0K
YoY Change 30.43% 24.44% 73.33%
% of Gross Profit
Operating Expenses $22.81M $19.38M $20.80M
YoY Change 60.97% 60.37% 77.79%
Operating Profit -$22.81M -$19.38M -$20.80M
YoY Change 78.37% 60.37% 77.79%
Interest Expense $1.070M $1.068M $826.0K
YoY Change 234.38% 206.9% 197.12%
% of Operating Profit
Other Income/Expense, Net -$180.0K -$40.00K -$30.00K
YoY Change 125.0% 100.0% 200.0%
Pretax Income -$21.92M -$18.35M -$20.00M
YoY Change 74.8% 56.17% 74.98%
Income Tax
% Of Pretax Income
Net Earnings -$21.92M -$18.35M -$20.00M
YoY Change 74.72% 56.14% 75.03%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$5.24 -$4.47 -$7.61
COMMON SHARES
Basic Shares Outstanding 42.32M 42.31M
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q4 2018 Q3 2018 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $171.1M $177.8M $186.0M
YoY Change
Cash & Equivalents $15.40M $28.90M $34.72M
Short-Term Investments $155.7M $148.9M $151.8M
Other Short-Term Assets $1.800M $2.000M $1.700M
YoY Change
Inventory
Prepaid Expenses
Receivables $0.00 $0.00 $0.00
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $173.0M $179.8M $187.6M
YoY Change 94.61%
LONG-TERM ASSETS
Property, Plant & Equipment $6.238M $6.345M $6.595M
YoY Change -10.35%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $0.00 $6.400M $12.10M
YoY Change
Other Assets $1.622M $1.624M $2.200M
YoY Change 213.13%
Total Long-Term Assets $8.410M $14.91M $20.88M
YoY Change -36.02%
TOTAL ASSETS
Total Short-Term Assets $173.0M $179.8M $187.6M
Total Long-Term Assets $8.410M $14.91M $20.88M
Total Assets $181.4M $194.7M $208.5M
YoY Change 77.78%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.847M $2.624M $1.900M
YoY Change 103.83%
Accrued Expenses $4.990M $4.618M $4.856M
YoY Change 49.49%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $16.58M $11.69M $9.400M
YoY Change 109.98%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $45.00K $64.00K $82.00K
YoY Change -61.86%
Total Long-Term Liabilities $45.00K $64.00K $82.00K
YoY Change -61.86%
TOTAL LIABILITIES
Total Short-Term Liabilities $16.58M $11.69M $9.400M
Total Long-Term Liabilities $45.00K $64.00K $82.00K
Total Liabilities $20.68M $15.21M $13.39M
YoY Change 84.97%
SHAREHOLDERS EQUITY
Retained Earnings -$163.3M -$141.4M
YoY Change 87.94%
Common Stock $324.7M $4.000K
YoY Change 7871.2%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $160.7M $179.5M $195.1M
YoY Change
Total Liabilities & Shareholders Equity $181.4M $194.7M $208.5M
YoY Change 77.78%

Cashflow Statement

Concept 2018 Q4 2018 Q3 2018 Q2
OPERATING ACTIVITIES
Net Income -$21.92M -$18.35M -$20.00M
YoY Change 74.72% 56.14% 75.03%
Depreciation, Depletion And Amortization $600.0K $560.0K $520.0K
YoY Change 30.43% 24.44% 73.33%
Cash From Operating Activities -$12.80M -$13.89M -$18.05M
YoY Change 10.34% 52.3% 84.56%
INVESTING ACTIVITIES
Capital Expenditures $440.0K $290.0K $430.0K
YoY Change 33.33% -23.68% -37.68%
Acquisitions
YoY Change
Other Investing Activities -$540.0K $8.920M -$92.37M
YoY Change -105.83% -23.43% 99.37%
Cash From Investing Activities -$990.0K $8.630M -$92.80M
YoY Change -111.07% -23.43% 97.4%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 300.0K -10.00K 82.25M
YoY Change -3100.0% -87.5% 135.81%
NET CHANGE
Cash From Operating Activities -12.80M -13.89M -18.05M
Cash From Investing Activities -990.0K 8.630M -92.80M
Cash From Financing Activities 300.0K -10.00K 82.25M
Net Change In Cash -13.49M -5.270M -28.60M
YoY Change 405.24% -354.59% 30.53%
FREE CASH FLOW
Cash From Operating Activities -$12.80M -$13.89M -$18.05M
Capital Expenditures $440.0K $290.0K $430.0K
Free Cash Flow -$13.24M -$14.18M -$18.48M
YoY Change 10.98% 49.26% 76.5%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2019 dei Document Transition Report
DocumentTransitionReport
false
CY2019 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2019 dei Entity Registrant Name
EntityRegistrantName
Unity Biotechnology, Inc.
CY2019 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-4726035
CY2019 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2019 dei Document Annual Report
DocumentAnnualReport
true
CY2019 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2019 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2019 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019 dei Entity Central Index Key
EntityCentralIndexKey
0001463361
CY2019 dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001
CY2019 dei Trading Symbol
TradingSymbol
UBX
CY2019 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
37473000
CY2019 dei Entity Shell Company
EntityShellCompany
false
CY2019 us-gaap Operating Expenses
OperatingExpenses
89651000
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-163278000
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
42414294
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
42414294
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
17216000
CY2018Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
45000
CY2018Q4 us-gaap Liabilities
Liabilities
20682000
CY2018Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-95000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
181375000
CY2018 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
58907000
CY2017 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
37373000
CY2017 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9617000
CY2019Q4 ubx License Agreement Contingent Consideration Liability Current
LicenseAgreementContingentConsiderationLiabilityCurrent
1131000
CY2018Q4 ubx License Agreement Contingent Consideration Liability Current
LicenseAgreementContingentConsiderationLiabilityCurrent
895000
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
16582000
CY2018Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
155736000
CY2019Q4 ubx Cash Cash Equivalents And Marketable Securities
CashCashEquivalentsAndMarketableSecurities
125000000
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-89651000
CY2019 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
3289000
CY2018 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
3312000
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-76398000
CY2017 us-gaap Net Income Loss
NetIncomeLoss
-44656000
CY2017 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-104000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15399000
CY2019Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
84508000
CY2018Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
2467000
CY2018Q4 ubx License Agreement Contingent Consideration Liability Noncurrent
LicenseAgreementContingentConsiderationLiabilityNoncurrent
1588000
CY2019Q4 us-gaap Liabilities
Liabilities
30514000
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
5000
CY2019Q4 us-gaap Equity Securities Fv Ni
EquitySecuritiesFvNi
5507000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1999000
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1830000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
129487000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
172965000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
16636000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6238000
CY2018Q4 us-gaap Settlement Liabilities Current
SettlementLiabilitiesCurrent
2059000
CY2019Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
13298000
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
4000
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
366695000
CY2018Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
324663000
CY2019Q4 ubx Related Party Promissory Notes For Purchase Of Common Stock
RelatedPartyPromissoryNotesForPurchaseOfCommonStock
210000
CY2018Q4 ubx Related Party Promissory Notes For Purchase Of Common Stock
RelatedPartyPromissoryNotesForPurchaseOfCommonStock
201000
CY2019Q4 ubx Employee Promissory Notes For Purchase Of Common Stock
EmployeePromissoryNotesForPurchaseOfCommonStock
418000
CY2018Q4 ubx Employee Promissory Notes For Purchase Of Common Stock
EmployeePromissoryNotesForPurchaseOfCommonStock
400000
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
90000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-245455000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
120707000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
160693000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
151221000
CY2019Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.0001
CY2018Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
10000000
CY2018Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
10000000
CY2019Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
0
CY2018Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
0
CY2019Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0
CY2018Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
47227065
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
47227065
CY2017 ubx Contribution Revenue
ContributionRevenue
1382000
CY2018 us-gaap Operating Income Loss
OperatingIncomeLoss
-79465000
CY2017 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1055000
CY2019 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
4185000
CY2018 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-245000
CY2017 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-103000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-82177000
CY2019 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
185000
CY2018 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
9000
CY2019 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-81992000
CY2017 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-182000
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
10852000
CY2018 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-76389000
CY2017 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-44760000
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.88
CY2018 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.70
CY2017 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-13.97
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
43624807
CY2018 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
28269907
CY2017 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3197516
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
-41536000
CY2017 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
8000
CY2017 ubx Vesting Of Early Exercised Options
VestingOfEarlyExercisedOptions
97000
CY2017 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
44000
CY2017 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3034000
CY2018 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
75852000
CY2018 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
233839000
CY2018 ubx Stock Issued During Period Value Upon Exercise Of Warrants And Stock Options
StockIssuedDuringPeriodValueUponExerciseOfWarrantsAndStockOptions
374000
CY2018 ubx Vesting Of Early Exercised Options
VestingOfEarlyExercisedOptions
584000
CY2018 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
9441000
CY2018 ubx Receipt Of Promissory Note From Related Party To Purchase Common Stock
ReceiptOfPromissoryNoteFromRelatedPartyToPurchaseCommonStock
390000
CY2018 ubx Receipt Of Promissory Note From Employees To Purchase Common Stock
ReceiptOfPromissoryNoteFromEmployeesToPurchaseCommonStock
400000
CY2018 ubx Repayment Of Promissory Note From Related Party
RepaymentOfPromissoryNoteFromRelatedParty
895000
CY2019 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
840000
CY2019 ubx Vesting Of Early Exercised Options
VestingOfEarlyExercisedOptions
647000
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10852000
CY2019 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2995000
CY2019 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
586000
CY2017 ubx Stock Issued During Period Value Stock Options Early Exercised
StockIssuedDuringPeriodValueStockOptionsEarlyExercised
5000
CY2018 ubx Common Stock Issuance Cost
CommonStockIssuanceCost
9149000
CY2018 ubx Stock Issued During Period Value Stock Options Early Exercised
StockIssuedDuringPeriodValueStockOptionsEarlyExercised
1212000
CY2019 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2663000
CY2018 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2180000
CY2017 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1304000
CY2019 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
1151000
CY2018 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
955000
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
9441000
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
3034000
CY2018 ubx Loss On Disposal Of Property And Equipment
LossOnDisposalOfPropertyAndEquipment
45000
CY2017 ubx Loss On Disposal Of Property And Equipment
LossOnDisposalOfPropertyAndEquipment
15000
CY2019 ubx Common Stock Granted To Third Party
CommonStockGrantedToThirdParty
965000
CY2017 ubx Common Stock Granted To Third Party
CommonStockGrantedToThirdParty
44000
CY2019 us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
4507000
CY2019 ubx Accretion Of Tenant Improvement Allowance
AccretionOfTenantImprovementAllowance
1275000
CY2018 ubx Accretion Of Tenant Improvement Allowance
AccretionOfTenantImprovementAllowance
605000
CY2017 ubx Accretion Of Tenant Improvement Allowance
AccretionOfTenantImprovementAllowance
605000
CY2018 ubx Increase Decrease In Contribution Receivable
IncreaseDecreaseInContributionReceivable
-1382000
CY2017 ubx Increase Decrease In Contribution Receivable
IncreaseDecreaseInContributionReceivable
1382000
CY2019 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
169000
CY2018 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
842000
CY2017 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
746000
CY2019 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
31000
CY2018 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
604000
CY2017 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-23000
CY2019 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-227000
CY2018 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2228000
CY2017 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1198000
CY2019 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
2114000
CY2018 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
1610000
CY2017 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
1607000
CY2019 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-587000
CY2018 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
1446000
CY2017 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
1258000
CY2019 ubx Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
2461000
CY2018 ubx Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
-93000
CY2017 ubx Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
366000
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-72421000
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-56623000
CY2017 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-38358000
CY2019 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
119270000
CY2018 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
204086000
CY2017 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
134465000
CY2019 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
188809000
CY2018 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
133644000
CY2017 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
49849000
CY2018 us-gaap Payments To Acquire Longterm Investments
PaymentsToAcquireLongtermInvestments
500000
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1586000
CY2018 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1264000
CY2017 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1689000
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
67953000
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-72206000
CY2017 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-86305000
CY2019 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
26085000
CY2018 us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
59881000
CY2017 us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
42867000
CY2019 ubx Proceeds From Issuance Of Common Stock Upon Exercise Of Stock Options Net Of Repurchase Payments
ProceedsFromIssuanceOfCommonStockUponExerciseOfStockOptionsNetOfRepurchasePayments
840000
CY2018 ubx Proceeds From Issuance Of Common Stock Upon Exercise Of Stock Options Net Of Repurchase Payments
ProceedsFromIssuanceOfCommonStockUponExerciseOfStockOptionsNetOfRepurchasePayments
374000
CY2017 ubx Proceeds From Issuance Of Common Stock Upon Exercise Of Stock Options Net Of Repurchase Payments
ProceedsFromIssuanceOfCommonStockUponExerciseOfStockOptionsNetOfRepurchasePayments
-37000
CY2019 ubx Proceeds From Issuance Of Common Stock Under Employee Stock Purchase Plan
ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan
586000
CY2018 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
79055000
CY2018 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
3201000
CY2018 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
895000
CY2019 us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
73000
CY2018 us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
74000
CY2017 us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
55000
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
27438000
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
136930000
CY2017 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
42775000
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
22970000
CY2018 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
8101000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
15949000
CY2019 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
565000
CY2017 us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
243000
CY2019 ubx Lessor Funded Lease Incentives Included In Property And Equipment
LessorFundedLeaseIncentivesIncludedInPropertyAndEquipment
10651000
CY2017 ubx Lessor Funded Lease Incentives Included In Property And Equipment
LessorFundedLeaseIncentivesIncludedInPropertyAndEquipment
3881000
CY2018 ubx Receipt Of Promissory Note For Purchase Of Common Stock
ReceiptOfPromissoryNoteForPurchaseOfCommonStock
400000
CY2019 ubx Receipt Of Promissory Note From Related Party To Purchase Common Stock
ReceiptOfPromissoryNoteFromRelatedPartyToPurchaseCommonStock
27000
CY2018Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
99000
CY2019 ubx Capital Lease Term Of Contract
CapitalLeaseTermOfContract
P3Y
CY2018Q4 us-gaap Shares Subject To Mandatory Redemption Settlement Terms Fair Value Of Shares
SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares
2000000
CY2019 ubx Fair Value Assets Hierarchy Levels Transfers Amount
FairValueAssetsHierarchyLevelsTransfersAmount
0
CY2018 ubx Fair Value Assets Hierarchy Levels Transfers Amount
FairValueAssetsHierarchyLevelsTransfersAmount
0
CY2019Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
124368000
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
92000
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1000
CY2019Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
124459000
CY2019 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company bases its estimates on historical experience and market-specific or other relevant assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities reported in the Company&#8217;s balance sheets and the amount of expenses and income reported for each of the periods presented are affected by estimates and assumptions, which are used for, but are not limited to, determining the fair value of assets and liabilities, contingent consideration liability, common stock valuation, and stock-based compensation. Actual results could differ from such estimates or assumptions. </p>
CY2018Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
4000
CY2018Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
169867000
CY2019 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentrations of Risk </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, restricted cash and marketable securities. Substantially all of the Company&#8217;s cash and cash equivalents and restricted cash is deposited in accounts with financial institutions that management believes are of high credit quality. Such deposits have and will continue to exceed federally insured limits. The Company maintains its cash with accredited financial institutions and accordingly, such funds are subject to minimal credit risk. The Company has not experienced any losses on its cash deposits. The contribution receivable is unsecured and is concentrated with one third-party organization, and accordingly the Company may be exposed to credit risk. To date, the Company has not experienced any loss related to its contributions receivable. </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s investment policy limits investments to certain types of securities issued by the U.S. government, its agencies and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash, cash equivalents, restricted cash and marketable securities and issuers of marketable securities to the extent recorded on the balance sheets. As of December&#160;31, 2019, the Company had no off-balance sheet concentrations of credit risk. </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is also exposed to market risk in its strategic investments. As of December 31, 2019, the Company held an investment in common stock which is publicly traded.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company depends on third-party suppliers for key raw materials used in its manufacturing processes and is subject to certain risks related to the loss of these third-party suppliers or their inability to supply the Company with adequate raw materials. </p>
CY2018Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
169962000
CY2019Q4 ubx Operating Leases Future Minimum Payments Due In Five Years And Thereafter
OperatingLeasesFutureMinimumPaymentsDueInFiveYearsAndThereafter
29272000
CY2018Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.33898
CY2018Q2 ubx Stockholders Equity Reverse Stock Split Effective Date
StockholdersEquityReverseStockSplitEffectiveDate
2018-04-20
CY2019 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7298000
CY2019Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
1446000
CY2018Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
550000
CY2017Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
550000
CY2019 us-gaap Concentration Risk Credit Risk Financial Instruments Off Balance Sheet Risk
ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk
As of December 31, 2019, the Company had no off-balance sheet concentrations of credit risk.
CY2019Q4 ubx Concentration Risk Credit Risk Off Balance Sheet Risk
ConcentrationRiskCreditRiskOffBalanceSheetRisk
0
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.40
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
13.20
CY2019Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
5373000
CY2019Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
6230000
CY2019Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
5859000
CY2019Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
4386000
CY2019 ubx Available For Sale Securities Maximum Remaining Contractual Maturity
AvailableForSaleSecuritiesMaximumRemainingContractualMaturity
P2Y
CY2019 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2019 ubx Compound Library And Option Agreement Execution Month And Year
CompoundLibraryAndOptionAgreementExecutionMonthAndYear
2016-02
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
22952000
CY2018Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
9888000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6316000
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3650000
CY2019 us-gaap Depreciation
Depreciation
2700000
CY2018 us-gaap Depreciation
Depreciation
2200000
CY2017 us-gaap Depreciation
Depreciation
1300000
CY2019Q4 ubx Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
2214000
CY2018Q4 ubx Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
1837000
CY2019Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
1849000
CY2018Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
783000
CY2019Q4 ubx Liability Related To Early Exercise Shares
LiabilityRelatedToEarlyExerciseShares
237000
CY2018Q4 ubx Liability Related To Early Exercise Shares
LiabilityRelatedToEarlyExerciseShares
885000
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
695000
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1485000
CY2019Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
4995000
CY2018Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
4990000
CY2019Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
51120000
CY2019Q4 ubx Number Of Promissory Note
NumberOfPromissoryNote
3
CY2019Q4 ubx Number Of Executive Officer
NumberOfExecutiveOfficer
2
CY2018Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
122000000
CY2018Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
140000000
CY2018Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
91739149
CY2018Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
103283818
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
3027802
CY2019 ubx Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Shares Added In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesAddedInPeriod
2357131
CY2019 ubx Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Granted In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantedInPeriod
2935629
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
467016
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
2916320
CY2019 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
505226
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
671319
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6906898
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
2574677
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
6906898
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
8.78
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.66
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
9.47
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.62
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
6.21
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
7.62
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y2M12D
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P7Y4M9D
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y2M12D
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
12297000
CY2019Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
7269000
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
12297000
CY2017 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.022
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
100000
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
1500000
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
5800000
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
7.12
CY2018Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
21900000
CY2017 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3034000
CY2018 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
0.003
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.133
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
40435000
CY2019Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
3436000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
3514000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
1473000
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
1040000
CY2019Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
947000
CY2018Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
3714000
CY2019 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
6221000
CY2019 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
173000
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.926
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.820
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10852000
CY2018 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9441000
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7427297
CY2018 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6591409
CY2017 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
34842052
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2018 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340
CY2019 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.022
CY2018 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.009
CY2019 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.009
CY2018 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.001
CY2019 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
-0.005
CY2019 ubx Effective Income Tax Rate Reconciliation Income Expense Tax Credits Research And Development
EffectiveIncomeTaxRateReconciliationIncomeExpenseTaxCreditsResearchAndDevelopment
-0.002
CY2018 ubx Effective Income Tax Rate Reconciliation Income Expense Tax Credits Research And Development
EffectiveIncomeTaxRateReconciliationIncomeExpenseTaxCreditsResearchAndDevelopment
0.010
CY2019 ubx Effective Income Tax Rate Reconciliation Reduction To State Net Operating Losses
EffectiveIncomeTaxRateReconciliationReductionToStateNetOperatingLosses
-0.039
CY2018 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.231
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.133
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0159
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.026
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.018
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0227
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.030
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.022
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.994
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.874
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.770
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.113
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
-0.185
CY2019 ubx Tax Cuts And Jobs Act Of2017 Net Operating Losses Carryforward Maximum Percentage Of Taxable Income
TaxCutsAndJobsActOf2017NetOperatingLossesCarryforwardMaximumPercentageOfTaxableIncome
0.80
CY2017 ubx Tax Cuts And Jobs Act Of2017 Valuation Allowance Deferred Tax Asset Change In Amount
TaxCutsAndJobsActOf2017ValuationAllowanceDeferredTaxAssetChangeInAmount
8300000
CY2018Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
29926000
CY2018Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
3865000
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1839000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Contingencies
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies
670000
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Contingencies
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsContingencies
954000
CY2019Q4 us-gaap Deferred Tax Assets Charitable Contribution Carryforwards
DeferredTaxAssetsCharitableContributionCarryforwards
253000
CY2018Q4 us-gaap Deferred Tax Assets Charitable Contribution Carryforwards
DeferredTaxAssetsCharitableContributionCarryforwards
253000
CY2019Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
49781000
CY2018Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
37877000
CY2019Q4 ubx Deferred Tax Liabilities Unrealized Gains On Equity Investments
DeferredTaxLiabilitiesUnrealizedGainsOnEquityInvestments
947000
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
48834000
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
37877000
CY2019 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
11000000
CY2018 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
17600000
CY2017 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
9400000
CY2019Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2017Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
3065000
CY2018 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
753000
CY2018 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
104000
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
9762000
CY2018Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
0
CY2018 us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
0
CY2019Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-19737000
CY2019Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
0
CY2019 us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
0
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-24470000
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-22354000
CY2019Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-23090000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-18767000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-23673000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-21710000
CY2019Q4 us-gaap Net Income Loss
NetIncomeLoss
-18027000
CY2019Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.44
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.56
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.51
CY2019Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.39
CY2018Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-16482000
CY2018Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-20798000
CY2018Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-19377000
CY2018Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-22808000
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-16133000
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-20002000
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-18346000
CY2018Q4 us-gaap Net Income Loss
NetIncomeLoss
-21917000
CY2018Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-4.69
CY2018Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.76
CY2018Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.45
CY2018Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.53

Files In Submission

Name View Source Status
0001564590-20-010071-index-headers.html Edgar Link pending
0001564590-20-010071-index.html Edgar Link pending
0001564590-20-010071.txt Edgar Link pending
0001564590-20-010071-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gzou35kfceum000001.jpg Edgar Link pending
gzou35kfceum000002.jpg Edgar Link pending
gzou35kfceum000003.jpg Edgar Link pending
gzou35kfceum000004.jpg Edgar Link pending
gzou35kfceum000005.jpg Edgar Link pending
gzou35kfceum000006.jpg Edgar Link pending
gzou35kfceum000007.jpg Edgar Link pending
gzou35kfceum000008.jpg Edgar Link pending
gzou35kfceum000009.jpg Edgar Link pending
gzou35kfceum000010.jpg Edgar Link pending
gzou35kfceum000011.jpg Edgar Link pending
gzou35kfceum000012.jpg Edgar Link pending
gzou35kfceum000013.jpg Edgar Link pending
gzou35kfceum000014.jpg Edgar Link pending
gzou35kfceum000015.jpg Edgar Link pending
gzou35kfceum000016.jpg Edgar Link pending
gzou35kfceum000017.jpg Edgar Link pending
gzou35kfceum000018.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
ubx-10k_20191231.htm Edgar Link pending
ubx-20191231.xml Edgar Link completed
ubx-20191231.xsd Edgar Link pending
ubx-20191231_cal.xml Edgar Link unprocessable
ubx-20191231_def.xml Edgar Link unprocessable
ubx-20191231_lab.xml Edgar Link unprocessable
ubx-20191231_pre.xml Edgar Link unprocessable
ubx-ex1025_1002.htm Edgar Link pending
ubx-ex1026_1001.htm Edgar Link pending
ubx-ex1027_1000.htm Edgar Link pending
ubx-ex1028_999.htm Edgar Link pending
ubx-ex1029_998.htm Edgar Link pending
ubx-ex1030_997.htm Edgar Link pending
ubx-ex1031_996.htm Edgar Link pending
ubx-ex231_9.htm Edgar Link pending
ubx-ex311_11.htm Edgar Link pending
ubx-ex312_7.htm Edgar Link pending
ubx-ex321_12.htm Edgar Link pending
ubx-ex44_501.htm Edgar Link pending